Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

cTTP is an Ultra-rare Blood Clotting Disorder Associated with Life-Threatening Acute Events and Debilitating Chronic Symptoms



ADZYNMA is the First and Only Recombinant ADAMTS13 Enzyme...

Related Keywords

United States ,Japan ,Japanese ,Yasushi Kajii ,Thromb Haemost ,Kremer Hovinga ,Van Dorland ,European Medicines Agency ,Japan Ministry Of Health ,Takeda Pharmaceutical Company Limited ,Exchange Commission ,Drug Administration ,Japanese Ministry Of Health ,Takeda Pharmaceuticals United Statesa Inc ,Japanese Ministry ,Orphan Drug Designation ,Product Overview ,Specific Populations ,Takeda Pharmaceuticals United Statesa ,Prescribing Information ,Annual Report ,Accessed March ,Rev Dis ,Thrombotic Thrombocytopenic ,Markets ,